# US 2021/0023116 A1 · Treatment of cancer by systemic administration of dbait molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0023116 A1
- Document ID: US20210023116A1
- Status: Published application
- Kind: A1
- Application number: 17/038,704
- Filed: 2020-09-30
- Published: 2021-01-28
- Earliest claimed: 2016-03-01
- Assignees: Onxeo; Institut Curie; Centre National De La Recherche Scientifique; Institut National de la Sante et de la Recherche Medicale
- Applicants: Onxeo; Institut Curie; Centre National De La Recherche Scientifique; Institut National De La Sante Et De La Recherche Medicale
- Inventors: MARIE DUTREIX; NATHALIE BERTHAULT
- Web page: https://patentgrep.com/patent/US20210023116A1

## CPC

- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/04: specific for metastasis
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/13: Decoys
- C12N 2310/315: Phosphorothioates
- C12N 2310/3183: Diol linkers, e.g. glycols or propanediols
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2310/531: Stem-loop; Hairpin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to the use of a DBait molecules by systemic routes without any combination with an endosomolytic agent.

## Claims

### Claim 1

A method of treating ovarian cancer comprising the administration, by a parenteral systemic route selected from intraperitoneal and intravenous administration to a subject having an ovarian cancer, a nucleic acid molecule of the following formula:
wherein N is a deoxynucleotide, n is an integer from 15 to 195, the underlined N refers to a nucleotide having or not a modified phosphodiester backbone, L′ is a linker, C is the molecule facilitating endocytosis selected from a lipophilic molecule or a ligand which targets cell receptor enabling receptor mediated endocytosis, L is a linker, m is an integer being 0 or 1 and p is 1; wherein the nucleic acid is to be used without combined administration of any quinoline endosomolytic agent.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the nucleic acid of formula (I) has one or several of the following features:
N is a deoxynucleotide selected from the group consisting of A (adenine), C (cytosine), T (thymine) and G (guanine) and selected so as to avoid occurrence of a CpG dinucleotide and to have less than 80% sequence identity to any gene in a human genome; and/or
the linked L′ is selected from the group consisting of hexaethyleneglycol, tetradeoxythymidylate (T4) and 1,19-bis(phospho)-8-hydraza-2-hydroxy-4-oxa-9-oxo-nonadecane; and/or
m is 1 and L is a carboxamido polyethylene glycol; and/or
C is selected from the group consisting of a cholesterol, single or double chain fatty acids and a ligand which targets cell receptor.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the nucleic acid molecule has one of the following formulae:
wherein the underlined nucleotide refers to a nucleotide having or not a phosphorothioate or methylphosphonate backbone, the linked L′ is selected from the group consisting of hexaethyleneglycol, tetradeoxythymidylate (T4) and 1,19-bis(phospho)-8-hydraza-2-hydroxy-4-oxa-9-oxo-nonadecane; m is 1 and L is a carboxamido oligoethylene glycol, C is selected from the group consisting of dioleoyl, octadecyl, folic acid, tocopherol and cholesterol.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the nucleic acid is
and wherein the underlined nucleotide refers to a nucleotide having a phosphorothioate backbone, the linked L′ is 1,19-bis(phospho)-8-hydraza-2-hydroxy-4-oxa-9-oxo-nonadecane; m is 1 and L is a carboxamido tetraethylene glycol, C is cholesterol.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the nucleic acid is to be administered by intravenous route.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the nucleic acid is to be administered by injection, intravenous drip, bolus or pump.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the nucleic acid is administered in combination with antitumor treatment.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the nucleic acid is administered in combination with radiotherapy and/or chemotherapy.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the nucleic acid is administered in combination with a DNA damaging anti-tumor agent.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the DNA damaging anti-tumor agent is selected from the group consisting of an inhibitor of topoisomerases I or II, a DNA crosslinker, a DNA alkylating agent, an anti-metabolic agent and inhibitors of the mitotic spindles.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the nucleic acid is to be used in combination with a platinum drug selected from the group consisting of oxaliplatin, carboplatin and cisplatin.

### Claim 12 (depends on 2)

The method according to claim 2, wherein L is carboxamido triethylene or tetraethylene glycol.

### Claim 13 (depends on 2)

The method according to claim 2, wherein C is selected from the group consisting of octadecyl, oleic acid, dioleoyl acid, stearic acid, tocopherol, cholesterol, folic acid, galactose, mannose, oligosaccharide of galactose and/or mannose, RGD, bombesin, integrin and transferrin.
